ezh2biologydiseaseandstructurebaseddrugdiscovery
文献类型:期刊论文
作者 | Tan Jinzhi; Yan Yan; Wang Xiaoxi; Jiang Yi![]() |
刊名 | actapharmacologicasinica
![]() |
出版日期 | 2014 |
卷号 | 35期号:2页码:161 |
关键词 | EZH2 PRC2 transcriptional repression gene activation anticancer drug crystal structure SET domain methyltransferase inhibitor epigenetic therapy |
ISSN号 | 1671-4083 |
英文摘要 | EZH2 is the catalytic subunit of the polycomb repressive complex 2 (PRC2), which is a highly conserved histone methyltransferase that methylates lysine 27 of histone 3. Overexpression of EZH2 has been found in a wide range of cancers, including those of the prostate and breast. In this review, we address the current understanding of the oncogenic role of EZH2, including its PRC2-dependent transcriptional repression and PRC2-independent gene activation. We also discuss the connections between EZH2 and other silencing enzymes, such as DNA methyltransferase and histone deacetylase. We comprehensively address the architecture of the PRC2 complex and the crucial roles of each subunit. Finally, we summarize new progress in developing EZH2 inhibitors, which could be a new epigenetic therapy for cancers. |
语种 | 英语 |
源URL | [http://119.78.100.183/handle/2S10ELR8/284608] ![]() |
专题 | 中国科学院上海药物研究所 |
作者单位 | 中国科学院上海药物研究所 |
推荐引用方式 GB/T 7714 | Tan Jinzhi,Yan Yan,Wang Xiaoxi,et al. ezh2biologydiseaseandstructurebaseddrugdiscovery[J]. actapharmacologicasinica,2014,35(2):161. |
APA | Tan Jinzhi,Yan Yan,Wang Xiaoxi,Jiang Yi,&Xu H Eric.(2014).ezh2biologydiseaseandstructurebaseddrugdiscovery.actapharmacologicasinica,35(2),161. |
MLA | Tan Jinzhi,et al."ezh2biologydiseaseandstructurebaseddrugdiscovery".actapharmacologicasinica 35.2(2014):161. |
入库方式: OAI收割
来源:上海药物研究所
浏览0
下载0
收藏0
其他版本
除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。